Actis Capital eyes $280 million Symbiotec Pharmalab exit2 min read . Updated: 12 Sep 2016, 08:50 PM IST
The stake sale deal would value Symbiotec Pharmalab at $400 million, with London-based Actis Capital, which owns 70%, standing to make $280 million
Mumbai: Private equity firm Actis Capital is looking to sell its majority stake in Indore-based Symbiotec Pharmalab Ltd, according to two people familiar with the development.
Select your Category